secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001493152-23-026002
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD announces positive Phase 2 topline results for MYMD-1 in sarcopenia/frailty
--------------------------------------------------------------------------------

- Study met primary endpoints: significantly reduced TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) levels.
- All pharmacokinetic and secondary safety/tolerability endpoints achieved; no treatment-related adverse events.
- Company to present data to FDA and intends to advance MYMD-1 into Phase 3 for sarcopenia.
- MYMD-1 is first oral TNF-α inhibitor candidate; potential first FDA-approved drug for sarcopenia if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/0001493152-23-026002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer